Biorce bets $52M on a new era of clinical trials
Barcelona-based healthtech company Biorce is preparing to deploy a fresh $52 million funding round to overhaul how global clinical trials are designed, run and evaluated. The company aims to set a new benchmark for speed, patient safety and regulatory-grade data quality by combining advanced AI algorithms, real-world data and a highly digital trial infrastructure.
Building a data-first clinical research platform
The core of Biorce‘s strategy is a unified platform that connects sponsors, investigators and patients across borders. By integrating electronic health records, wearable data and remote monitoring tools, the company wants to reduce the heavy operational burden that has long slowed down drug development.
According to the company, the new capital will be directed into three main areas: scaling its cloud-based clinical trial management system, expanding global site and patient networks, and investing in regulatory-compliant data analytics capabilities. This approach is designed to support both traditional randomized studies and emerging decentralized clinical trials, which allow patients to participate from home.
Raising the bar on speed, quality and inclusion
Shorter timelines, stronger evidence
Biorce says its technology can streamline patient recruitment, automate eligibility checks and improve protocol adherence. By using predictive AI models to identify optimal sites and patient cohorts, the company aims to cut months from typical study timelines while improving data completeness and reducing protocol deviations.
Global reach and patient-centric design
The Barcelona hub gives Biorce access to both European and global research ecosystems. The company plans to use the funding to deepen collaborations with hospitals, research centers and biopharma companies, while designing trials that are more inclusive of underrepresented populations. Remote consent, multilingual patient interfaces and continuous digital follow-up are central to this patient-first strategy.
Positioning as a new standard-setter
With regulators and sponsors demanding more robust real-world evidence and resilient trial operations, Biorce is positioning itself as a technology partner that can meet stringent global requirements. If the $52M roadmap succeeds, the company could help define a new operational standard for clinical research, where digital tools, automation and data science are embedded in every phase of the trial lifecycle.